OncoVista Innovative Therapies Inc  

(Public, OTCMKTS:OVIT)   Watch this stock  
Find more results for OTC:OVIT
-0.0140 (-40.00%)
Aug 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.02 - 0.02
52 week 0.01 - 0.09
Open 0.02
Vol / Avg. 11,000.00/39,265.00
Mkt cap 494,730.00
P/E     -
Div/yield     -
EPS -0.15
Shares 23.56M
Beta -3.86
Inst. own 5%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -2928.10% -4675.90%
Return on average equity - -
Employees 3 -
CDP Score - -


14785 Omicron Dr Ste 104
SAN ANTONIO, TX 78245-3222
United States - Map
+1-210-6776000 (Phone)


OncoVista Innovative Therapies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The Company's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The Company's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The Company's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.

Officers and directors

Alexander L. Weis Ph.D. Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary
Age: 65